Literature DB >> 1794077

Neurogenic pain syndromes and their management.

D Bowsher1.   

Abstract

Neurogenic pain is defined as pain due to dysfunction of the peripheral or central nervous system, in the absence of nociceptor (nerve terminal) stimulation by trauma or disease. Other terms used to describe some (but not all) forms of neurogenic pain include neuropathic pain, deafferentation pain, and central pain; all these terms are subsumed into the wider expression 'neurogenic pain'. The clinical syndromes representing this type of disorder make up at least 25% of the patients attending most pain clinics. This is undoubtedly proportionately greater than its incidence in chronic pain as a whole, and is a measure of its intractability and of the therapeutic dilemma which it presents. However, neurogenic pain syndromes are much commoner than is perhaps generally recognized: when all categories are taken into account, there are probably more than 550,000 cases in the UK population of 56 million at any one time, i.e. a prevalence of about 1%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794077     DOI: 10.1093/oxfordjournals.bmb.a072498

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  24 in total

Review 1.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

2.  Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners.

Authors:  Ariel Berger; Piotr Kramarz; Gry Stine Kopperud; John Edelsberg; Gerry Oster
Journal:  Eur J Health Econ       Date:  2007-01-13

Review 3.  The management of postherpetic neuralgia.

Authors:  D Bowsher
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

4.  Paradoxical pain.

Authors:  D Bowsher
Journal:  BMJ       Date:  1993-02-20

5.  Central pain: clinical and physiological characteristics.

Authors:  D Bowsher
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

6.  Enhancement of GABAA receptor-mediated conductances induced by nerve injury in a subclass of sensory neurons.

Authors:  A A Oyelese; D L Eng; G B Richerson; J D Kocsis
Journal:  J Neurophysiol       Date:  1995-08       Impact factor: 2.714

Review 7.  TNF-alpha and neuropathic pain--a review.

Authors:  Lawrence Leung; Catherine M Cahill
Journal:  J Neuroinflammation       Date:  2010-04-16       Impact factor: 8.322

8.  Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey.

Authors:  Janet Weber; Marcus Schley; Matthias Casutt; Helmut Gerber; Guido Schuepfer; Roman Rukwied; Wolfgang Schleinzer; Michael Ueberall; Christoph Konrad
Journal:  Anesthesiol Res Pract       Date:  2009-10-25

9.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.

Authors:  Mohab M Ibrahim; Hongfeng Deng; Alexander Zvonok; Debra A Cockayne; Joyce Kwan; Heriberto P Mata; Todd W Vanderah; Josephine Lai; Frank Porreca; Alexandros Makriyannis; T Philip Malan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

Review 10.  The management of central post-stroke pain.

Authors:  D Bowsher
Journal:  Postgrad Med J       Date:  1995-10       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.